Despite professional society guidelines recommending that obesity be treated as a chronic disease by emphasizing the use of lifestyle modification in conjunction with pharmacotherapy, anti-obesity medications are uncommonly prescribed in most clinical practices. The recent FDA approval of semaglutide 2.4 mg weekly to treat obesity – as well as other forthcoming advancements in diabetes and anti-obesity medications – highlights the potential of pharmacotherapy to significantly augment weight loss efforts. In this Expert Endocrine Consult, we review the evolving role of anti-obesity pharmacotherapy in clinical practice and suggest a framework for the use of these medications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.